Cardiovascular biotech Trevena sets terms for $75 million IPO

By Renaissance Capital,

Shutterstock photo

Trevena, a clinical-stage biotech developing treatments for acute heart failure, announced terms for its IPO on Wednesday. The King of Prussia, PA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Trevena would command a market value of $291 million.

Trevena, which was founded in 2007, plans to list on the NASDAQ under the symbol TRVN. Trevena initially filed confidentially on September 6, 2013. Barclays and Jefferies are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: TRVN

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by